Baseline Characteristics for the 188 Women With Premenopausal Breast Cancer Treated With Adjuvant Chemotherapy
| Age (y) | 45.9 ± 5.5 |
| BMI (kg/m2) | 26.1 ± 6.4 |
| Race (% White) | 64% |
| Lumbar spine BMD (g/cm2) | 1.002 ± 0.11 |
| Femoral neck BMD (g/cm2) | 0.797 ± 0.10 |
| 25 hydroxyvitamin D (ng/mL) | 31.2 ± 10.1 |
| FSH (IU/L) | 45.8 ± 34.2 |
| Currently menstruating (% yes) | 16% |
| Time from end of chemotherapy to baseline visit (d) | 302 ± 148 |
| Treatment includes tamoxifen (% yes) | 57% |
| Chemotherapy received (%) | |
| Adriamycin | 57% |
| Cyclophosphamide | 72% |
| Fluorouracil | <1% |
| Methotrexate | <1% |
| Phenylalanine mustard | <1% |
| Paclitaxel | 50% |
| Docetaxel | 30% |
| Other | 17% |
| Do not know | 4% |
| Age (y) | 45.9 ± 5.5 |
| BMI (kg/m2) | 26.1 ± 6.4 |
| Race (% White) | 64% |
| Lumbar spine BMD (g/cm2) | 1.002 ± 0.11 |
| Femoral neck BMD (g/cm2) | 0.797 ± 0.10 |
| 25 hydroxyvitamin D (ng/mL) | 31.2 ± 10.1 |
| FSH (IU/L) | 45.8 ± 34.2 |
| Currently menstruating (% yes) | 16% |
| Time from end of chemotherapy to baseline visit (d) | 302 ± 148 |
| Treatment includes tamoxifen (% yes) | 57% |
| Chemotherapy received (%) | |
| Adriamycin | 57% |
| Cyclophosphamide | 72% |
| Fluorouracil | <1% |
| Methotrexate | <1% |
| Phenylalanine mustard | <1% |
| Paclitaxel | 50% |
| Docetaxel | 30% |
| Other | 17% |
| Do not know | 4% |
Values are mean ± SD or %. BMD, bone mineral density.
Baseline Characteristics for the 188 Women With Premenopausal Breast Cancer Treated With Adjuvant Chemotherapy
| Age (y) | 45.9 ± 5.5 |
| BMI (kg/m2) | 26.1 ± 6.4 |
| Race (% White) | 64% |
| Lumbar spine BMD (g/cm2) | 1.002 ± 0.11 |
| Femoral neck BMD (g/cm2) | 0.797 ± 0.10 |
| 25 hydroxyvitamin D (ng/mL) | 31.2 ± 10.1 |
| FSH (IU/L) | 45.8 ± 34.2 |
| Currently menstruating (% yes) | 16% |
| Time from end of chemotherapy to baseline visit (d) | 302 ± 148 |
| Treatment includes tamoxifen (% yes) | 57% |
| Chemotherapy received (%) | |
| Adriamycin | 57% |
| Cyclophosphamide | 72% |
| Fluorouracil | <1% |
| Methotrexate | <1% |
| Phenylalanine mustard | <1% |
| Paclitaxel | 50% |
| Docetaxel | 30% |
| Other | 17% |
| Do not know | 4% |
| Age (y) | 45.9 ± 5.5 |
| BMI (kg/m2) | 26.1 ± 6.4 |
| Race (% White) | 64% |
| Lumbar spine BMD (g/cm2) | 1.002 ± 0.11 |
| Femoral neck BMD (g/cm2) | 0.797 ± 0.10 |
| 25 hydroxyvitamin D (ng/mL) | 31.2 ± 10.1 |
| FSH (IU/L) | 45.8 ± 34.2 |
| Currently menstruating (% yes) | 16% |
| Time from end of chemotherapy to baseline visit (d) | 302 ± 148 |
| Treatment includes tamoxifen (% yes) | 57% |
| Chemotherapy received (%) | |
| Adriamycin | 57% |
| Cyclophosphamide | 72% |
| Fluorouracil | <1% |
| Methotrexate | <1% |
| Phenylalanine mustard | <1% |
| Paclitaxel | 50% |
| Docetaxel | 30% |
| Other | 17% |
| Do not know | 4% |
Values are mean ± SD or %. BMD, bone mineral density.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
